Re: Myriad Genetics, Inc. - Registration Statement on Form S-3 (Registration No. 333-31734)
Dear Ladies and Gentlemen: Pursuant to Rule 477(a) promulgated under the Securities Act of 1933, as amended, Myriad Genetics, Inc. (the "Registrant") hereby respectfully requests that the Securities and Exchange Commission consent to the withdrawal of its Registration Statement on Form S-3 (Registration No. 333-31734), together with all exhibits and amendments thereto (the "Registration Statement"). The Registrant is requesting such withdrawal because of unfavorable market conditions that would adversely affect the offering of the shares of common stock, par value $.01 per share, covered by the Registration Statement.
The Registrant further requests that, pursuant to Rule 477(c), an order with the date of the granting of the withdrawal be included in the file for the above-captioned Registration Statement in the following manner: "Withdrawn upon the request of the Registrant, the Commission consenting thereto."
Please address any questions you may have to Edward P. Gonzales, Esquire, at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111, telephone number (617) 542-6000, facsimile number (617) 542-2241.
Well, I came looking for more information on Celltech and why the run of late. Is it not odd that I am the one providing the information now?
Medeva information from before the merger showed a great pipeline company that was faltering on execution. They had a joint venture go bad with Abbott back in 1998, and they have a plant burndown (or explode) in 1999. So they had a great pipeline, but no way to produce thier patented stuff. They were also paying larege dividends about once every three or four quarters.
Along comes the merger to create Celltech. I was seriously considering dumping my shares at that time since it was not clear if they were going to have SEC approval to trade the new stock as ADRs, but they would be seeking. I was nervous that I would have a stock that I could not trade. Well I decided to ride it out, and I am glad that I did.
Okay now for some future stuff: From reading the merger notes, you will find that they have formed the largest biotech company in the EU with strong distribution in the US. This is great since they have a great pipeline with the aging baby boomers. They stand to have a very bright future.